Penobscot Investment Management Company Inc. Has $1.37 Million Stock Position in STERIS plc (NYSE:STE)

Penobscot Investment Management Company Inc. decreased its position in shares of STERIS plc (NYSE:STE - Free Report) by 33.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,657 shares of the medical equipment provider's stock after selling 3,350 shares during the period. Penobscot Investment Management Company Inc.'s holdings in STERIS were worth $1,368,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of STE. Avalon Trust Co acquired a new position in STERIS during the 4th quarter worth about $30,000. Human Investing LLC acquired a new position in shares of STERIS during the fourth quarter worth approximately $31,000. Anfield Capital Management LLC grew its stake in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 91 shares during the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of STERIS by 65.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC raised its position in STERIS by 182.7% in the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 137 shares during the last quarter. Institutional investors own 94.69% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Stephens reiterated an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research note on Thursday, February 6th. Finally, Piper Sandler lifted their price objective on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, STERIS currently has an average rating of "Moderate Buy" and a consensus target price of $258.75.

STERIS Trading Up 1.9 %

Shares of NYSE:STE traded up $4.14 during mid-day trading on Monday, reaching $227.14. The stock had a trading volume of 584,196 shares, compared to its average volume of 527,809. The firm has a 50 day simple moving average of $222.86 and a two-hundred day simple moving average of $221.01. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The firm has a market cap of $22.32 billion, a PE ratio of 48.22 and a beta of 0.92. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, research analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 21st. Shareholders of record on Thursday, February 20th were issued a dividend of $0.57 per share. The ex-dividend date was Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.00%. STERIS's dividend payout ratio is presently 48.41%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.